<DOC>
	<DOCNO>NCT00236470</DOCNO>
	<brief_summary>The primary purpose study document long-term safety oral formulation risperidone treatment child adolescent conduct disruptive behavior disorder . Data efficacy drug also collect . Only patient enrol previous related study would eligible participate .</brief_summary>
	<brief_title>A Study Safety Risperidone Treatment Children Adolescents With Conduct Other Disruptive Behavior Disorders</brief_title>
	<detailed_description>This open-label study oral formulation risperidone take daily 12 month child adolescent conduct disruptive behavior disorder . It extension randomize , double-blind study ( RIS-INT-79 ) compare risperidone placebo 6 month patient already show response medication period 12 week . Efficacy assessment include : Conduct Problem subscale Nisonger Child Behavior Rating Form ( N-CBRF ) , measure symptom conduct disruptive behavior disorder ; Visual Analogue Scale troublesome symptom ( VAS-MS ) , scale range troublesome extremely troublesome ; Clinical Global Impression-Severity Illness ( CGI-Severity ) , measure overall severity illness ; Children 's Global Assessment Scale ( C-GAS ) , assessment overall functioning . Safety evaluation include incidence adverse event , physical examination , laboratory test ( biochemistry , hematology , urinalysis ) , electrocardiogram ( ECGs ) . Oral risperidone solution ( 1milligram/milliliter ) daily 1year . For patient weigh least 50kg , start dose 0.5ml/day . At investigator 's discretion , dose may increase ( maximum 1.5ml/d 5 day ) . Patients 50kg start 0.25ml/d , increase , require , maximum 0.75ml/d .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Problem Behavior</mesh_term>
	<mesh_term>Attention Deficit Disruptive Behavior Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Patients must complete doubleblind study ( CR002020 ) Patients must begin present study within 7 day take last dose medication prior study ( CR002020 ) Patients hypersensitivity intolerance risperidone Patients extrapyramidal symptom ( EPS ) adequately controlled medication History neuroleptic malignant syndrome , rare psychotropicdrug reaction , may characterize confusion , reduce consciousness , high fever pronounce muscle stiffness Significant untreated unstable medical illness diabetes , hypertension serious illness liver , kidney , significant disturbance cardiac , pulmonary , gastrointestinal , endocrine , neurological system Pregnant nursing female , lack adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Disruptive behavior disorder</keyword>
	<keyword>risperidone</keyword>
	<keyword>antipsychotropic agent</keyword>
	<keyword>child</keyword>
	<keyword>adolescent</keyword>
</DOC>